A Phase 2 interventional study of Imatinib Mesylate and Ruxolitinib in Eosinophilic Myeloid Neoplasm and Hypereosinophilic Syndrome, sponsored by National Institutes of Health Clinical Center (CC). Active, not recruiting at 1 site in United States. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by National Institutes of Health Clinical Center (CC) · Phase 2, Interventional, and Treatment
Klion AD, Noel P, Akin C, Law MA, Gilliland DG, Cools J, Metcalfe DD, Nutman TB. Elevated serum tryptase levels identify a subset of patients with a myeloproli…PubMed 12676775 ↗; 2 more
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Hypereosinophilic Syndrome with a site in United States — 3 open to participants now, 8 under way, 3 of them phase 3. Hypereosinophilic Syndrome · United States.
Among the 23 studies in Hypereosinophilic Syndrome with a site in United States, this one is the 10th largest by enrollment of the 21 interventional ones that give a count, is the only one that started in 2002, is one of 8 in phase 2, and was the 3rd registered.
40 studies on the registry are indexed under Hypereosinophilic Syndrome; 8 are open to participants now.
Browse Hypereosinophilic Syndrome studies →3 of the 23 studies in Hypereosinophilic Syndrome with a site in United States are open now. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Argentina, Austria and 11 more countries
Ages 6+
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18–99
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 1–100 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 7 Hypereosinophilic Syndrome studies recruiting now, 5 set no upper age limit and none stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.
This study: 2 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 11 · Phase 3 8 · Phase 4 1
First in 1998; this study’s year is marked. 1 started in 2002.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 70 is above the median of 41 across 31 interventional studies indexed under Hypereosinophilic Syndrome.
Median enrollment 68 across the 21 interventional studies, 150 across the 2 observational. Of the 14 that completed or were terminated, 8 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 23 have an industry lead sponsor. The 9 most frequent:
National Institutes of Health Clinical Center (CC) is the lead sponsor of 376 studies on the registry; 27 are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 19 (83%) have results posted.
National Institutes of Health Clinical Center (CC) has 1 study filed under Hypereosinophilic Syndrome — fewer than ten, so there is no comparison to draw.
3 of the studies in Hypereosinophilic Syndrome with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05334368Phase 3GlaxoSmithKlineDepemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial | 2027-10-29 |
| NCT06477653National Institute of Allergy and Infectious Diseases (NIAID)Dupilumab as Add-On Therapy for Hypereosinophilic Syndrome With Partial Clinical Response to Eosinophil-Depleting Biologic Agents | 2026-12-30 |
| NCT03862157M.D. Anderson Cancer CenterAzacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | 2027-01-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 23 studies in Hypereosinophilic Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy of the tyrosine kinase inhibitors, imatinib mesylate and ruxolitinib in reducing peripheral blood eosinophilia in patients with myeloid and/or steroid-refractory hypereosinophilic syndrome (HES). Patients with HES who meet a set of criteria designed to select patients with the myeloid form of the disease, as well as patients without myeloid disease who are refractory to steroid therapy for HES, will be eligible. Imatinib mesylate will be initiated at a dose of 400 mg daily, the FDA-approved dose for the treatment of chronic myelogenous leukemia (CML), in participants with a known imatinib-sensitive mutation and in participants with myeloid features without a JAK mutation. If patients fail imatinib or are steroid-resistant and do not have myeloid features, ruxolitinib therapy will be initiated at a dose of 15 mg twice daily. Patients who demonstrate a clinical and hematologic response at 1 (imatinib arm) or 3 (ruxolitinib arm) months will be eligible to continue therapy. In patients who demonstrate a complete clinical and hematologic response to imatinib therapy (including those who received imatinib prior to enrollment), imatinib may be discontinued. Patients in complete remission for ≥5 years following imatinib are considered cured and will be taken off protocol. Patients receiving ruxolitinib who demonstrate drug-related toxicity and/or a sustained clinical response to ruxolitinib for >2 years may undergo dose de-escalation.
This study will evaluate the safety and effectiveness of imatinib mesylate and ruxolitinib in reducing the number of eosinophils (a type of white blood cell) in patients with hypereosinophilic syndrome (HES). Patients with HES have elevated counts of eosinophils in the blood and body tissues, which can cause damage to these tissues. Although HES can involve any tissues, the heart, nerves, and skin are most often affected. Several drugs, including steroids, interferon, and hydroxyurea can lower eosinophil counts; however, these drugs have drawbacks in that they do not work in all patients with HES, or they may work only temporarily, or patients may develop side effects that require stopping the drugs. At the time of study initiation, imatinib mesylate was a new drug approved to treat gastrointestinal tumors and chronic myelogenous leukemia. Some data suggested that imatinib mesylate might be useful in treating a subgroup of patients with HES. The study was subsequently amended to assess long-term response to imatinib and cure in patients with HES. An additional arm was later added to assess the safety and efficacy of ruxolitinib for the treatment of steroid-refractory HES.
Patients with HES who are two (2) years of age and older may be eligible for the imatinib arm of the study. Patients with HES who are 18 years or older may be eligible for the ruxolitinib arm of the study. Candidates will be screened with a medical history, physical examination, blood tests, electrocardiogram (EKG), echocardiogram (ultrasound examination of the heart), pulmonary (lung) function tests, eye exam and a bone marrow examination to determine if they fall into the subgroup of patients likely to respond to these therapies. For the bone marrow procedure, an area of skin and bone is numbed and a very sharp needle is inserted into the bone to draw out a sample of bone marrow for evaluation under the microscope.
Patients enrolled in the imatinib arm of the study will take imatinib mesylate daily. Patients enrolled on the ruxolitinib arm of the study will take ruxolitinib twice daily. Any other drugs they may be taking for HES, as well as other drugs they are taking that may interact with the study treatment, will be tapered and stopped. If it is not possible to stop taking certain drugs for other conditions, their dosages may be adjusted. Patients will be monitored weekly with laboratory testing during the first month of treatment and whenever neutrophil counts drop below 1500/mm\^3 or platelets fall below 100,000/mm\^3. If blood counts remain high enough, monitoring will be reduced to every 2 weeks for three (3) months and once a month after that. Patients receiving imatinib will have a clinic visit at NIH one (1) month after beginning the drug for a clinical and laboratory evaluation, including a repeat bone marrow examination. Patients receiving ruxolitinib will have a clinic visit at NIH 1 month after beginning the drug for a clinical and laboratory evaluation, and at 3 months for repeat evaluation, including a repeat bone marrow examination. Patients receiving imatinib whose eosinophil counts are not lowered after 4 weeks of treatment will leave the study. Those who respond to therapy will return to NIH every 3 months for a history and physical examination, laboratory tests, EKG, echocardiogram, and pulmonary function testing to determine how treatment is affecting disease progression. In some participants with stable disease where an optimal dose of imatinib mesylate has been identified, visits may be extended to every six months. Patients who achieve clinical, hematologic and molecular remission for > 2 years may undergo treatment interruption to assess for durable cure. Patients receiving ruxolitinib will undergo clinical assessments at 1 and 3 months, with repeat bone marrow examination after a minimum of 2 months of therapy. Clinical responders will continue on study with assessment every 3 months for at least one year, after which the interval between visits may be extended. In addition to the clinical assessments, the following procedures will be done solely for research purposes:
The criteria were revised on the registry on Nov 12, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
In order to be eligible to participate in this study, an individual must meet all of the following criteria:
All participants must fit one of the following four categories:
Presence of >=4 of the following laboratory criteria suggestive of a myeloid disorder:
NOTE: Participants who meet inclusion criteria but are already receiving imatinib, may be enrolled in the dose de-escalation portion of the study at the investigator's discretion. Patients who meet inclusion criteria but are already receiving ruxolitinib may be enrolled at the investigator's discretion if baseline data are available and they have received ruxolitinib at the dose specified in the protocol for less than 2 months (primary endpoint).
**Effective contraception includes the use of hormonal (birth control pills, for example) and/or barrier (condoms and diaphragms, for example) methods by participants and/or their partners to prevent pregnancy in women of childbearing potential. For women of childbearing potential who use hormonal methods as their primary means of contraception and will be receiving treatment with ruxolitinib, barrier methods will also be required due to possible interference of ruxolitinib with hormonal contraceptives.
Although a private physician is not required for inclusion in the study, it is strongly recommended that all participants have a physician outside the NIH for routine medical care and emergencies.
EXCLUSION CRITERIA:
An individual who meets any of the following criteria will be excluded from participation in this study:
An individual who meets any of the following criteria will be excluded from participation in the ruxolitinib treatment arm of this study:
Treatment with fluconazole >200 mg daily.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Children age two years and above and adults with steroid-refractory hypereosinophilic syndrome (HES) and FIP1L1::PDGFRA or translocations involving PDGFRB received imatinib mesylate 400 mg oral daily for three months with option to continue treatment for up to twenty years. Imatinib interruption was attempted after a minimum of two years of sustained hematologic and, if appropriate, molecular response.
Drug: Imatinib Mesylate
Children age two years and above and adults with steroid-refractory hypereosinophilic syndrome (HES) and features suggestive of a myeloid neoplasm without FIP1L1::PDGFRA or a translocation involving PDGFRB, received imatinib mesylate 400 mg oral daily for three months with option to continue treatment for up to twenty years. Imatinib interruption was attempted after a minimum of two years of sustained hematologic response. If participants failed imatinib, ruxolitinib therapy could be initiated at 15 mg oral twice daily.
Drug: Imatinib Mesylate · Drug: Ruxolitinib
Children age two years and above and adults with steroid-refractory hypereosinophilic syndrome (HES) and no features suggestive of a myeloid neoplasm received imatinib mesylate 400 mg oral daily for three months with option to continue treatment for up to twenty years. Imatinib interruption was attempted after 20 years of sustained hematologic response. If participants failed imatinib, ruxolitinib therapy could be initiated at 15 mg oral twice daily.
Drug: Imatinib Mesylate · Drug: Ruxolitinib
Adults with steroid-refractory FIP1L1::PDGFRA-negative, PDGFRB translocation negative, BCR::ABL-negative hypereosinophilic syndrome (HES) without myeloid features, or with a known molecular abnormality involving the Janus kinase-signal transducers and activators of transcription (JAK-STAT) pathway or with imatinib-resistant HES with myeloid features received ruxolitinib 15 mg orally twice daily for up to eight years.
Drug: Imatinib Mesylate
Initial dosing regimen is 400 mg oral once daily in adults and 260 mg/m\^2/day in children with food and a glass of water
Also known as: Gleevec
Initially dosing regimen is 15 mg orally twice daily
Also known as: Jakafi
Percentage of Participants With an Absolute Eosinophil Count Levels in the Normal Range (<860/mm^3)
The efficacy of treatment in reducing eosinophilia was estimated after the initiation of treatment as the percentage of participants who reached an absolute eosinophil count (AEC) levels in the normal range defined AEC \<860/mm\^3 following initiation of therapy. AEC was measured at the same time of day in each participant at specified times before and after treatment.
Time frame: One month (for imatinib) and 3 months (for ruxolitinib)
Percentage of Participants With an Absolute Eosinophil Count (AEC) Levels Below 1500/mm^3
The efficacy of treatment in reducing eosinophilia was estimated after the initiation of treatment as the percentage of participants who achieved an absolute eosinophil count (AEC) levels below 1500/mm\^3 following initiation of therapy.
Time frame: One month (for imatinib) and three months (for ruxolitinib) during initial analysis; 12 months for both imatinib and ruxolitinib
| Milestone | Drug Therapy 1a: Imatinib Mesylate in Participants With FIP1L1::PDGFRA or PDGFRB Translocations | Drug Therapy 1b: Imatinib Mesylate in Participants With Myeloid Neoplasm | Drug Therapy 1c: Imatinib Mesylate in Participants With Non-myeloid Neoplasm | Drug Therapy 2: Ruxolitinib |
|---|---|---|---|---|
| Started | 26 | 12 | 8 | 19 |
| Started on ruxolitinib after one month of imatinib therapy | 0 | 1 | 2 | 0 |
| Completed | 25 | 12 | 7 | 19 |
| Not completed | 1 | 0 | 1 | 0 |
| Withdrew: Death | 1 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 1 | 0 |
The efficacy of treatment in reducing eosinophilia was estimated after the initiation of treatment as the percentage of participants who reached an absolute eosinophil count (AEC) levels in the normal range defined AEC \<860/mm\^3 following initiation of therapy. AEC was measured at the same time of day in each participant at specified times before and after treatment.
| percentage of participants | Drug Therapy 1a: Imatinib Mesylate in Participants With FIP1L1::PDGFRA or PDGFRB Translocations | Drug Therapy 1b: Imatinib Mesylate in Participants With Myeloid Neoplasm | Drug Therapy 1c: Imatinib Mesylate in Participants With Non-myeloid Neoplasm | Drug Therapy 2: Ruxolitinib |
|---|---|---|---|---|
| Percentage of Participants With an Absolute Eosinophil Count Levels in the Normal Range (<860/mm^3) | 100 | 16.67 | 25 | 63.64 |
The efficacy of treatment in reducing eosinophilia was estimated after the initiation of treatment as the percentage of participants who achieved an absolute eosinophil count (AEC) levels below 1500/mm\^3 following initiation of therapy.
| percentage of participants | Drug Therapy 1a: Imatinib Mesylate in Participants With FIP1L1::PDGFRA or PDGFRB Translocations | Drug Therapy 1b: Imatinib Mesylate in Participants With Myeloid Neoplasm | Drug Therapy 1c: Imatinib Mesylate in Participants With Non-myeloid Neoplasm | Drug Therapy 2: Ruxolitinib |
|---|---|---|---|---|
| One month (imatinib) and three months (ruxolitinib) | 100 | 33.33 | 28.57 | 86.36 |
| Twelve months | 100 | 50 | — | 83.33 |
Collected over Participants were monitored for adverse events from one month and up to 20 year depending on duration on drug; Ruxolitinib - three months to eight years. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Drug Therapy 1a: Imatinib Mesylate in Participants With FIP1L1::PDGFRA or PDGFRB Translocations | 4/26 (15.4%) | 9/26 (34.6%) | 19/26 (73.1%) |
| Drug Therapy 1b: Imatinib Mesylate in Participants With Myeloid Neoplasm | 0/12 (0%) | 3/12 (25%) | 4/12 (33.3%) |
| Drug Therapy 1c: Imatinib Mesylate in Participants With Non-myeloid Neoplasm | 0/8 (0%) | 0/8 (0%) | 3/8 (37.5%) |
| Drug Therapy 2: Ruxolitinib | 2/22 (9.1%) | 11/22 (50%) | 21/22 (95.5%) |
| Event | Drug Therapy 1a: Imatinib Mesylate in Participants With FIP1L1::PDGFRA or PDGFRB Translocations | Drug Therapy 1b: Imatinib Mesylate in Participants With Myeloid Neoplasm | Drug Therapy 1c: Imatinib Mesylate in Participants With Non-myeloid Neoplasm | Drug Therapy 2: Ruxolitinib |
|---|---|---|---|---|
| SepsisInfections and infestations | 0/26 | 0/12 | 0/8 | 2/22 |
| Mitral valve diseaseCardiac disorders | 0/26 | 1/12 | 0/8 | 1/22 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 1/26 | 1/12 | 0/8 | 0/22 |
| Acute lymphocytic leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/26 | 1/12 | 0/8 | 0/22 |
| Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders | 0/26 | 1/12 | 0/8 | 0/22 |
| LymphopeniaBlood and lymphatic system disorders | 0/26 | 0/12 | 0/8 | 1/22 |
| Cardiac failure congestiveCardiac disorders | 0/26 | 0/12 | 0/8 | 1/22 |
| BlindnessEye disorders | 0/26 | 0/12 | 0/8 | 1/22 |
| ColitisGastrointestinal disorders | 0/26 | 0/12 | 0/8 | 1/22 |
| VomitingGastrointestinal disorders | 0/26 | 0/12 | 0/8 | 1/22 |
| Event | Drug Therapy 1a: Imatinib Mesylate in Participants With FIP1L1::PDGFRA or PDGFRB Translocations | Drug Therapy 1b: Imatinib Mesylate in Participants With Myeloid Neoplasm | Drug Therapy 1c: Imatinib Mesylate in Participants With Non-myeloid Neoplasm | Drug Therapy 2: Ruxolitinib |
|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 3/26 | 0/12 | 0/8 | 7/22 |
| DiarrhoeaGastrointestinal disorders | 4/26 | 2/12 | 2/8 | 4/22 |
| Urinary tract infectionInfections and infestations | 0/26 | 0/12 | 0/8 | 5/22 |
| ThrombocytosisBlood and lymphatic system disorders | 0/26 | 0/12 | 0/8 | 4/22 |
| COVID-19Infections and infestations | 0/26 | 0/12 | 0/8 | 4/22 |
| FractureInjury, poisoning and procedural complications | 1/26 | 0/12 | 0/8 | 4/22 |
| Rash pruriticSkin and subcutaneous tissue disorders | 0/26 | 0/12 | 0/8 | 4/22 |
| Skin lesionSkin and subcutaneous tissue disorders | 0/26 | 0/12 | 0/8 | 4/22 |
| LymphopeniaBlood and lymphatic system disorders | 1/26 | 0/12 | 0/8 | 3/22 |
| InfluenzaInfections and infestations | 0/26 | 0/12 | 0/8 | 3/22 |
| Age, Categorical(Participants) | Drug Therapy 1a: Imatinib Mesylate in Participants With FIP1L1::PDGFRA or PDGFRB Translocations | Drug Therapy 1b: Imatinib Mesylate in Participants With Myeloid Neoplasm | Drug Therapy 1c: Imatinib Mesylate in Participants With Non-myeloid Neoplasm | Drug Therapy 2: Ruxolitinib | Total |
|---|---|---|---|---|---|
| <=18 years | 1 | 2 | 0 | 0 | 3 |
| Between 18 and 65 years | 24 | 7 | 7 | 16 | 54 |
| >=65 years | 1 | 3 | 1 | 3 | 8 |
| Sex: Female, Male(Participants) | Drug Therapy 1a: Imatinib Mesylate in Participants With FIP1L1::PDGFRA or PDGFRB Translocations | Drug Therapy 1b: Imatinib Mesylate in Participants With Myeloid Neoplasm | Drug Therapy 1c: Imatinib Mesylate in Participants With Non-myeloid Neoplasm | Drug Therapy 2: Ruxolitinib | Total |
|---|---|---|---|---|---|
| Female | 1 | 6 | 5 | 12 | 24 |
| Male | 25 | 6 | 3 | 7 | 41 |
| Ethnicity (NIH/OMB)(Participants) | Drug Therapy 1a: Imatinib Mesylate in Participants With FIP1L1::PDGFRA or PDGFRB Translocations | Drug Therapy 1b: Imatinib Mesylate in Participants With Myeloid Neoplasm | Drug Therapy 1c: Imatinib Mesylate in Participants With Non-myeloid Neoplasm | Drug Therapy 2: Ruxolitinib | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 0 | 2 | 2 | 6 |
| Not Hispanic or Latino | 24 | 11 | 5 | 16 | 56 |
| Unknown or Not Reported | 0 | 1 | 1 | 1 | 3 |
| Race (NIH/OMB)(Participants) | Drug Therapy 1a: Imatinib Mesylate in Participants With FIP1L1::PDGFRA or PDGFRB Translocations | Drug Therapy 1b: Imatinib Mesylate in Participants With Myeloid Neoplasm | Drug Therapy 1c: Imatinib Mesylate in Participants With Non-myeloid Neoplasm | Drug Therapy 2: Ruxolitinib | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 1 | 0 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 7 | 3 | 1 | 2 | 13 |
| White | 15 | 8 | 4 | 15 | 42 |
| More than one race | 2 | 0 | 0 | 1 | 3 |
| Unknown or Not Reported | 1 | 0 | 3 | 1 | 5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — This study will comply with the NIH Data Sharing Policy and Policy on the Dissemination of NIH-Funded Clinical Trial Information and the Clinical Trials Registration and Results Information Submission rule. As such, this trial will be registered at ClinicalTrials.gov, and results information from this trial will be submitted to ClinicalTrials.gov. In addition, every attempt will be made to publish results in peer-reviewed journals.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Data can be requested after publication.
Access criteria: Data from this study may be requested from other researchers at any time after the completion of the primary endpoint by contacting the PI.
Ran from Sep 2002 to primary completion in Nov 2023, 253 months.
Results were first posted in Nov 2026, 2 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
Klion AD, Noel P, Akin C, Law MA, Gilliland DG, Cools J, Metcalfe DD, Nutman TB. Elevated serum tryptase levels identify a subset of patients with a myeloproli…PubMed 12676775 ↗; 2 more
Klion AD, Noel P, Akin C, Law MA, Gilliland DG, Cools J, Metcalfe DD, Nutman TB. Elevated serum tryptase levels identify a subset of patients with a myeloproli…PubMed 12676775 ↗; 2 more
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ruxolitinib
National Institutes of Health Clinical Center (CC) →